NESS ZIONA, Israel, Nov. 14, 2025 (WORLD NEWSWIRE)– BiomX Inc. (NYSE: PHGE) (” BiomX” or the “Business”), a clinical-stage business advancing unique natural and crafted phage treatments targeting particular pathogenic germs, today revealed that it means to effect a one-for-nineteen reverse split (the “Reverse Stock Split”) of the Business’s typical stock (the “Common Stock”). The Common Stock will continue to trade on the NYSE American under the existing sign “PHGE” and will start trading on a split-adjusted basis when the marketplace opens on November 25, 2025. The brand-new CUSIP number for the Common Stock following the Reverse Stock Split will be 09090D 509.
The Reverse Stock Split was formerly authorized by the Business’s investors at the 2025 Yearly Fulfilling of Stockholders hung on October 16, 2025, with the last ratio figured out by the Business’s Board of Directors on November 13, 2025. The Business prepares to submit a Certificate of Change to the Business’s Certificate of Incorporation with the Secretary of State of the State of Delaware to effect the Reverse Stock Split.
The 1-for-19 Reverse Stock Split will immediately integrate and transform nineteen present shares of the Common Stock into one released and exceptional brand-new share of Common Stock. Proportional changes likewise will be made to shares underlying exceptional equity awards, warrants and convertible favored stock, and to the variety of shares released and issuable under the Business’s stock reward strategies and specific existing arrangements. The Reverse Stock Split will not alter the par worth of the Common Stock nor the authorized variety of shares of Common Stock, chosen stock or any series of favored stock.
The Reverse Stock Split will impact all investors evenly and will not change any shareholder’s portion ownership interest in the Business’s equity, other than for small modifications to the treatment of fractional shares as explained listed below. After the efficiency of the Reverse Stock Split, the variety of exceptional shares of Common Stock will be minimized from roughly 29,006,165 to roughly 1,526,640 based on modification to provide impact to the treatment of any fractional shares that investors would have gotten in the Reverse Stock Split. No fractional shares of Common Stock will be released in connection with the Reverse Stock Split. Stockholders of the Business who otherwise would be entitled to get fractional shares due to the fact that they hold a variety of shares not uniformly divisible by the Reverse Stock Split ratio will be immediately entitled to get an extra portion of a share of the Common Stock to assemble to the next entire share. Continental Stock Transfer & & Trust Business, the Business transfer representative, will send out directions to investors of record who hold stock certificates relating to the exchange of certificates for Common Stock. Investors who hold their shares of Common Stock in book-entry type or in brokerage accounts or “street name” are not needed to take any action to effect the exchange of their shares of Common Stock following the Reverse Stock Split. Continental Stock Transfer & & Trust Business might be grabbed concerns at (800) 509-5586.
About BiomX
BiomX is a clinical-stage business leading the advancement of natural and crafted phage mixed drinks and individualized phage treatments developed to target and damage damaging germs for the treatment of persistent illness with significant unmet requirements. BiomX finds and confirms exclusive bacterial targets and uses its BOLT (” BacteriOphage Result In Treatment”) platform to personalize phage structures versus these targets. To learn more, please visit www.biomx.com, the material of which does not form a part of this news release.
Safe Harbor
This news release consists of reveal or suggested “positive declarations” within the significance of the “safe harbor” arrangements of the U.S. Personal Securities Lawsuits Reform Act of 1995. Positive declarations can be recognized by words such as: “target,” “think,” “anticipate,” “will,” “may,” “expect,” “quote,” “would,” “located,” “future,” and other comparable expressions that forecast or show future occasions or patterns or that are not declarations of historic matters. For instance, when BiomX goes over the efficient date for the Reverse Stock Split and the date that trading of the Common Stock will start on a split-adjusted basis, it is utilizing positive declarations. Positive declarations are neither historic truths nor guarantees of future efficiency. Rather, they are based just on BiomX management’s present beliefs, expectations and presumptions. Due to the fact that positive declarations connect to the future, they go through intrinsic unpredictabilities, dangers and modifications in situations that are challenging to forecast and much of which are beyond BiomX’s control. For that reason, financiers need to not depend on any of these positive declarations and need to evaluate the dangers and unpredictabilities explained under the caption “Danger Elements” in BiomX’s Yearly Report on Kind 10-K submitted with the Securities and Exchange Commission (the “SEC”) March 25, 2025, and extra disclosures BiomX makes in its other filings with the SEC, which are offered on the SEC’s site at www.sec.gov. Positive declarations are made since the date of this news release, and other than as offered by law BiomX specifically disclaims any responsibility or carrying out to upgrade positive declarations.
Contacts:
BiomX, Inc.
Ben Cohen
Head Corporate Communications
benc@biomx.com